Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
MannKind Corporation MNKD
$4.19
-$0.05 (-1.30%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
1115078900.00000000
-
week52high
5.73
-
week52low
2.61
-
Revenue
99770000
-
P/E TTM
-10
-
Beta
1.58131400
-
EPS
-0.32000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 28 февр 2022 г. |
| RBC Capital | Sector Perform | 14 мая 2021 г. | |
| SVB Leerink | Outperform | Outperform | 05 мар 2021 г. |
| Oppenheimer | Outperform | 24 дек 2019 г. | |
| BTIG Research | Buy | 14 мая 2019 г. | |
| SVB Leerink | Outperform | Outperform | 09 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Singh Sanjay R | A | 218500 | 218500 | 01 ноя 2022 г. |
| Thomson David | D | 726035 | 7000 | 29 авг 2022 г. |
| Tross Stuart A | D | 816472 | 14178 | 27 авг 2022 г. |
| Castagna Michael | D | 2048534 | 35952 | 27 авг 2022 г. |
| Binder Steven B. | D | 714819 | 14178 | 27 авг 2022 г. |
| Kocinsky Joseph | D | 745233 | 12813 | 27 авг 2022 г. |
| Thomson David | D | 733035 | 14178 | 27 авг 2022 г. |
| Galindo Alejandro | D | 777075 | 15 | 22 авг 2022 г. |
| Galindo Alejandro | D | 777090 | 4600 | 22 авг 2022 г. |
| Galindo Alejandro | A | 781690 | 5000 | 31 июл 2022 г. |
Новостная лента
Why Shares of MannKind Are Up Wednesday
The Motley Fool
10 мая 2023 г. в 12:02
MannKind had a big jump in revenue year over year. The company has benefitted from its collaboration agreement with United Therapeutics.
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
GlobeNewsWire
10 мая 2023 г. в 06:00
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 2:05 pm (ET) at the InterContinental New York Barclay.
MannKind Corporation (MNKD) Q1 2023 Earnings Call Transcript
Seeking Alpha
09 мая 2023 г. в 21:29
MannKind Corporation (NASDAQ:MNKD ) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Michael Castagna - CEO Steven Binder - CFO Conference Call Participants Oren Livnat - HC Wainwright Brandon Folkes - Cantor Fitzgerald Thomas Smith - SVB Securities Steven Lichtman - Oppenheimer Anthony Petrone - Mizuho Operator Good afternoon. And welcome to the MannKind Corporation 2023 First Quarter Financial Results Earnings Call.
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 18:20
MannKind (MNKD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.10 per share a year ago.
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
GlobeNewsWire
02 мая 2023 г. в 17:00
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, May 9, 2023.